A pilot study investigating health related quality of life, symptom burden and prognostic markers in advanced soft tissue sarcoma

Principal Investigators: 

Dr Julia Riley, Dr Claire Smith, and Professor Ian Judson

Institution: 
Award Amount: 
£126,409
Duration: 
2 years

This study looks at the quality of life of patients being treated for advanced sarcoma. Prospective means it looks at patients as they go along, which gives stronger data. This is better than retrospective data which looks at events in the past where memory or uncertainty often makes the information unreliable.

People with locally advanced or sarcoma that has spread or whose sarcoma has have had recurred after surgery may only be eligible for palliative treatment so quality of life becomes the primary concern rather than defeating the sarcoma.

Identification of direct downstream targets of the PAX3-FOXO1 and MYCN proteins in alveolar rhabdomyosarcoma as potential therapeutic targets

Principal Investigators: 

ProfessorJanet Shipley, Dr Zoe Walters, and Dr Edoardo Missiaglia

Award Amount: 
£23,266
Duration: 
1 year

Deaths from cancer in children are, thankfully, rare. However, a leading cause of cancer related deaths in children is rhabdomyosarcoma, a soft tissue sarcoma. More effective treatments are urgently required and Dr Shipley proposed that increased understanding of the underlying molecular mechanisms in development and spread of rhabdomyosarcoma would yield new angles for investigation. 

24. Evaluation of loco-regional delivery of oncolytic virotherapy in a rat model of isolated limb perfusion

Principal Investigators: 

Professor Kevin Harrington and Dr Tim Pencavel

Award Amount: 
£30,014
Duration: 
2 years

This is an example of a translational research project, looking at ways to transfer results from the laboratory into a clinical trial in patients in a Phase 1 Trial. They are developing a system for treating limb sarcomas using Isolated Limb Perfusion (ILP) as well as oncolyic virotherapy (anti-cancer viruses)

Defects of DNA repair genes and cell cycle regulators as a predisposing cause of Sarcomas

Principal Investigators: 

Dr Karen Sisley, Dr Abdulazeez Salawu, and Dr Martin Robinson

Award Amount: 
£75,790
Duration: 
3 years

This is a basic science project, finding out more about how chromosome abnormalities in the nuclei of sarcoma cells might upset the regulation of cell turnover. If they can understand more about this it might be an opening to developing new approaches to treatment. 

Analysis of osteolysis in Ewing’s Sarcoma and the effect of resorption inhibitors on tumour growth

Principal Investigators: 
Institution: 
Award Amount: 
£17,500
Duration: 
2 years

Ewing's sarcoma is a highly aggressive bone tumour which predominantly affects children, adolescents and young adults. It is a tumour that causes extensive bone destruction and can spread rapidly. The bone destruction in Ewing’s is caused by osteoclasts, specialised bone cells which normally breakdown bone in balance with osteoblasts which build it up  This study aims to look more closely at the way Ewing’s cells promote osteoclast formation which then knocks normal bone biology out of kilter, increasing bone destruction.

Studies in angiosarcoma using canine tumours

Principal Investigators: 
Award Amount: 
£17,500
Duration: 
2 years

In humans angiosarcomas are rare, aggressive tumours of blood vessels.  Angiogenesis is the process of new blood vessel formation and is controlled by a number of different growth factors. The researchers think it is likely that these growth factors are important in the development of angiosarcoma, and that treatments targeting these factors will be useful for patients with angiosarcoma.  Whilst human angiosarcoma is rare the tumour is much more common in dogs and it will be seen by vets in their surgeries when your GP will never see a case.

Genomic and expression profiling of recurrent well differentiated and dedifferentiated liposarcomas

Principal Investigators: 

Professor Janet Shipley, Dr Anastasia Constantinidou

Award Amount: 
£25,000
Duration: 
2 years

Liposarcomas are a type of soft tissue sarcoma that arises in fat cells. Well-differentiated (WD) liposarcomas have clear cell walls and a regular appearence under the microscope. De-differentiated (DD) liposarcomas are much messier and irregular. Both are the most frequent subtype of liposarcomas in adults. Well-differentiated liposarcomas can recur looking more like the de-differentiated type. This is associated with increased aggressiveness. In contrast, completely well-differentiated liposarcomas are usually readily curable.

New therapeutic agents for chordoma

Principal Investigators: 
Award Amount: 
£28,000
Duration: 
2 years

Professor Flanagan is considered a leading expert in the field of chordoma research, both in the UK and internationally. Chordoma is a primary cancer of the bone that occurs in people of all ages. Due to the size, location and nature of these tumours, surgeons can often find them difficult to remove fully. Despite this, surgery is the mainstay of treatment because the tumours are resistant to radio- and chemotherapy. This project is undertaking lab-based experiments to identify new therapies to treat this disease.

Functional evaluation of survivors of paediatric bone and soft tissue tumours - a pilot study of two new technologies

Principal Investigators: 
Award Amount: 
£30,039
Duration: 
6 months

Validation of clinically relevant oncogenic receptors in high grade human sarcoma as potential drug targets

Principal Investigators: 
Award Amount: 
£17,000
Duration: 
1 year

Despite advances in conventional chemotherapy and radiation, complete cures for most cancer types, including sarcoma, remain elusive. The challenge is to develop highly targeted therapies that kill cancer cells but leave normal cells healthy. A big advance in cancer treatment in the past 20 years has been the discovery and application of ‘targeted therapies’. Targeted therapies are medicines that specifically act on parts of the sarcoma cells and either kill the cells or stop them growing.

Pages